Antibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Immunocytochemistry [1]
- Flow cytometry [1]
- Other assay [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MA1-19602 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CD63 Monoclonal Antibody (MEM-259), FITC
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- This antibody reacts with an extracellular/luminal epitope of CD63 (LAMP-3), a 40-60 kDa tetraspan glycoprotein expressed by granulocytes, platelets, T cells, monocytes/macrophages and endothelial cells. Cell surface exposition of CD63 is usually activation-dependent.
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Green dye
- Isotype
- IgG
- Antibody clone number
- MEM-259
- Vial size
- 100 Tests
- Storage
- 4° C, store in dark, DO NOT FREEZE!
Submitted references Extracellular vesicles mediated exocytosis of antisense peptide nucleic acids.
CRB3 and the FERM protein EPB41L4B regulate proliferation of mammary epithelial cells through the release of amphiregulin.
Endometrial exosomes/microvesicles in the uterine microenvironment: a new paradigm for embryo-endometrial cross talk at implantation.
Malik S, Saltzman WM, Bahal R
Molecular therapy. Nucleic acids 2021 Sep 3;25:302-315
Molecular therapy. Nucleic acids 2021 Sep 3;25:302-315
CRB3 and the FERM protein EPB41L4B regulate proliferation of mammary epithelial cells through the release of amphiregulin.
Walker SJ, Selfors LM, Margolis BL, Brugge JS
PloS one 2018;13(11):e0207470
PloS one 2018;13(11):e0207470
Endometrial exosomes/microvesicles in the uterine microenvironment: a new paradigm for embryo-endometrial cross talk at implantation.
Ng YH, Rome S, Jalabert A, Forterre A, Singh H, Hincks CL, Salamonsen LA
PloS one 2013;8(3):e58502
PloS one 2013;8(3):e58502
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescence analysis of CD63 was performed using 70% confluent log phase THP-1 cells differentiated into Macrophage (M0 phase). The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 15 minutes, and blocked with 1% BSA for 1 hour at room temperature. The cells were labeled with CD63, FITC Mouse Monoclonal Antibody (MEM-259) (Product # MA1-19602) at 1:100 dilution in 0.1% BSA, incubated at 4 degree Celsius overnight (Panel a: green). Nuclei (Panel b: blue) were stained with ProLong™ Diamond Antifade Mountant with DAPI (Product # P36962). F-actin (Panel c: red) was stained with Rhodamine Phalloidin (Product # R415, 1:300). Panel d represents the merged image showing membrane localization. Panel e shows undifferentiated cells with no signal. Panel f represents control cells with Isotype control to assess background. The images were captured at 60X magnification.
- Conjugate
- Green dye
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Flow cytometry analysis of peripheral blood lymphocytes from a patient with allergy to bee venom after stimulation with bee venom, stained with anti-human CD63 (MEM-259) FITC Monoclonal antibody (Product # MA1-19602).
- Conjugate
- Green dye
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 3 Detection of TEVs via flow cytometry (A) Workflow depicting the steps used for detection of TEVs using flow cytometry. TEVs were collected from the supernatant of untreated HeLa cells (blank TEVs) or cells treated with PNA-155 (1 h) followed by washing and incubation in serum-free media for 24 h (PNA-TEVs). TEVs collected after ultracentrifugation were conjugated with latex/aldehyde beads followed by incubation of bead-TEVs complex with FITC-conjugated antibodies and detected by flow cytometry. (B) A representative histogram of blank TEVs and PNA TEVs. (C) Representative flow cytometry dot plots of blank TEVs and PNA TEVs showing staining with CD-63, CD-81, and CD-9 FITC-conjugated antibodies. First row represents blank TEVs and second row represents PNA TEVs. The 2 nd , 3 rd , and 4 th columns indicate staining with CD-81, CD-63, and CD-9 antibodies, respectively. 50,000 events were collected for each sample and all events were included in the dot plots.
- Conjugate
- Green dye
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig 6 CRB3 expression leads to an increase in the number and size of CD63-positive puncta, and loss of EPB41L4B in the CRB3 background reverts this phenotype. (A) Confocal imaging of endocytic markers shows that CRB3 expression results in an increase in the number and size of endocytic vesicles, including those of early (EEA1) and late (LAMP-2, CD63) endosomes. Scale bars, 50 mum. Insets provide a higher magnification view of the same field to highlight vesicular structures. (B) Loss of EPB41L4B (but not AREG) reverts the dispersion of CD63-positive puncta in the CRB3 expressing cells. Control cells or CRB3-expressing cells with the indicated siRNA treatments were imaged by confocal (top) to quantify the average number of CD63-positive puncta per cell (bottom). The number of CD63-postive puncta increases approximately 10-fold upon CRB3 expression and is reverted to numbers close to vector control by loss of EPB41L4B. Error bars shown are +/-SD for the average number of CD63-positive puncta per cell from counts on 20-25 cells per condition and are representative of three independent experiments (**p
- Conjugate
- Green dye